Organigram Holdings Announces Upcoming Shareholder Meeting

Published 03/03/2025, 21:34
Organigram Holdings Announces Upcoming Shareholder Meeting

Organigram Holdings Inc. (NASDAQ:OGI), a Canadian company specializing in pharmaceutical preparations with a market capitalization of $56.19 million, announced today the scheduling of its Annual General and Special Meeting of Shareholders. The meeting is set to take place virtually, as detailed in the company’s latest SEC filing. According to InvestingPro data, the company maintains strong liquidity with a current ratio of 6.69, indicating robust short-term financial stability.

According to the filing submitted on March 3, 2025, the meeting is scheduled to occur on an unspecified date, with management information circulars dated February 12, 2025, already distributed to shareholders. The documents include a form of proxy and a virtual meeting guide, indicating the company’s preparedness for the upcoming event.

The announcement is part of Organigram’s compliance with SEC regulations, which require foreign private issuers like Organigram to report specific events and updates. The company, listed under the SIC code 2834 for pharmaceutical preparations, operates under the organization name 03 Life Sciences and is incorporated in zone Z4. InvestingPro analysis reveals two key challenges: the company is currently experiencing rapid cash burn and carries a significant debt burden. Subscribers can access 10 additional exclusive insights about Organigram’s financial position.

Organigram Holdings, with its principal executive offices located in Toronto, Ontario, Canada, files annual reports under the cover of Form 40-F, as indicated in the SEC filing. The business address is listed as 35A English Dr., Moncton, with the same address for mail correspondence.

The company’s Chief Financial Officer, Greg Guyatt, signed the SEC report, ensuring the registrant’s compliance with the Securities Exchange Act of 1934. The filing reflects the company’s administrative processes and adherence to regulatory requirements without disclosing specific financial data or business performance metrics.

The announcement is primarily directed at Organigram’s shareholders, who are encouraged to participate in the upcoming meeting to discuss company matters and vote on various issues. The use of a virtual meeting format reflects the ongoing trend of remote engagement in corporate governance, a practice that has become increasingly common among publicly traded companies.

This news is based on a press release statement and provides Organigram’s stakeholders with the necessary information regarding the upcoming shareholder meeting. With the company’s next earnings report scheduled for March 14, 2025, investors seeking deeper insights into Organigram’s financial health (currently rated as FAIR by InvestingPro) and market position can access comprehensive analysis and real-time updates through the platform’s advanced tools and metrics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.